Category Archives: Actos

Featured Stories

Actos Whistleblower Lawsuit Questions Avandia Researcher's Financial Ties to Takeda

A prominent researcher has been implicated in an alleged cover-up of Actos side effects, according to a report from TheHeart.org. An Actos whistleblower lawsuit unsealed earlier this year has alleged financial connections between the Cleveland Clinic’s Dr Steven Nissen and the maker of Actos “should be considered when analyzing Actos’s ...

Read More

Metal-on-Metal Hip Implant Lawyer Takes Issue with Statements Made by DePuy Orthpaedics Official During FDA Meeting

An attorney with a national law firm that represents victims of alleged metal-on-metal hip implant injuries has expressed dismay at some statements made last week regarding the regulation of all-metal hip replacement devices by an official with DePuy Orthopaedics. According to Daniel Burke, Senior Litigation Counsel at Parker ...

Read More

FDA Questions Device Makers about Duodenoscope Cleaning Procedures

Following Deadly Outbreaks, FDA Questions Device Makers about Duodenoscope Cleaning Procedures

In light of a recent outbreak linked to contaminated duodenoscopes, the U.S. Food and Drug Administration (FDA) is questioning manufacturers about their methods for cleaning the devices, the New York Times reports. The specialized scopes, which have been linked to several outbreaks in recent years, most recently infected seven patients ...

Read More

Research Study Confirms Fracking Cause of Ohio Earthquakes

Research Study Confirms Fracking as Cause of Ohio Earthquakes

Fracking operation near Poland Township, Ohio, activated a previously unknown fault in the, causing 77 earthquakes with magnitudes ranging from 1.0 to 3.0 in March 2014.

Read More

Birth Control Shot Depo-Provera may Increase HIV Risk

Birth Control Shot Depo-Provera may Increase HIV Risk, Study Suggests

A new study has linked the use of Depo-Provera (medroxyprogesterone acetate), an injectable type of birth control, to an increased risk of HIV infection.

Read More

Study Finds SSRI Antidepressant Side Effects Outweigh Their Benefits

A new study is raising more concerns about the safety of commonly used antidepressants, including selective serotonin reuptake (SSRI) inhibitor antidepressants. Investigators who conducted the study, which is published in the journal Frontiers in Psychology, posit that increased knowledge of the negative effects of SSRIs and other antidepressants could reduce ...

Read More

Actos, Avandia May Up Risk for Diabetic Macular Edema

A newly published study is raising concerns that patients who take Actos or Avandia may face an increased risk of developing diabetic macular edema, an eye disorder that can result in vision loss. The study, published in the Archives of Internal Medicine, found that type 2 diabetics who use thiazolidinediones, ...

Read More

New York Property Owners Challenge Binghamton Fracking Ban

According to a Reuters report, the landowners believe the Binghamton, N.Y., city council and Mayor acted against proper protocol when voting to ban fracking drilling the the city. Instead, they feel the city should have consulted with the Broome County Planning Commission before approving the ban.

Read More

EMA Seeks Stronger Pradaxa Guidance for Bleeding Side Effects

Regulators in Europe have again asked Boehringer Ingelheim, the manufacturer of the blood thinner Pradaxa, to update the drug’s label with additional information regarding Pradaxa bleeding side effects. According to the European Medicines Agency (EMA), the new guidance should include more specific information on when Pradaxa must not be used, ...

Read More

FDA Advisory Panel Wrestling with Metal-on-Metal Hip Replacement Safety

An advisory panel for the U.S. Food & Drug Administration (FDA) began a highly-anticipated meeting yesterday to discuss the safety of metal-on-metal hip implants. Among other things, the panel of outside experts is being asked to make recommendations regarding the best practices for monitoring patients with metal-on-metal hip replacements. ...

Read More

Controversial Diabetes Drug Actos Still on the Market

Controversial Diabetes Drug Actos Still on the Market

Though research has shown an association between the type 2 diabetes drug Actos and serious side effects including bladder cancer, heart failure, liver failure, and bone fractures, the Food and Drug Administration (FDA) has stopped short of recalling Actos. Actos … Continue reading

Posted in Actos, Pharmaceuticals | Tagged , , , , |

Actos Makers Continue to Face Bladder Cancer Claims

Actos Makers Continue to Face Bladder Cancer Claims

Lawsuits continue to be filed over Actos, a type 2 diabetes drug developed by Takeda and Eli Lilly. Plaintiffs in the litigation allege that Actos contributed to bladder cancer. Drug makers are accused of failing to disclose this risk to … Continue reading

Posted in Actos, Pharmaceuticals | Tagged , , , , |

Actos Bladder Cancer Cases Continue to be Filed

In the continuing controversy over the link between the type 2 diabetes drug Actos (pioglitazone) and bladder cancer, a new lawsuit was filed in June 2016 by a man who was diagnosed with bladder cancer after taking Actos for six … Continue reading

Posted in Actos, Defective Products, Health Concerns, Pharmaceuticals |

Diabetes Drug Pioglitazone Linked to Increased Risk of Bladder Cancer

An increased risk of bladder cancer has been uncovered following a large population-based study concerning patients who take the diabetes drug pioglitazone known to most as Actos, the Renal and Urology News reports. Pioglitazone is a single-ingredient product sold under … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

$2.4 Billion Settlement Announced in Actos Bladder Cancer Cases

$2.4B Settlement Announced in Actos Bladder Cancer Cases

On Tuesday, Takeda Pharmaceuticals announced a settlement that could go as high as $2.7 billion to resolve thousands of lawsuits from patients and their families who claim the diabetes drug Actos (pioglitazone) caused their bladder cancer. The New York Times … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals | Tagged , , , |

Jury Awards $2 Million in Actos Case

Late last week, a Pennsylvania jury ordered Takeda Pharmaceuticals to pay more than $2 million to a woman who claimed her bladder cancer was caused by the company’s diabetes drug Actos (pioglitazone). The jury found that Takeda officials failed to … Continue reading

Posted in Actos, Legal News, Pharmaceuticals |

Actos Litigation Update: Takeda Pharmaceutical Company, Eli Lilly and Company Ordered to Pay $9 Billion in Punitive Damages

Takeda Pharmaceutical Company and Eli Lilly and Company were just ordered to pay a total of $9 billion in punitive damages over Actos litigation involving bladder cancer allegations. Takeda and Eli Lilly lost a bid to have the Actos trial … Continue reading

Posted in Actos, Pharmaceuticals |

Jury Deliberations Begin in Nevada Actos Trial

On Tuesday, a jury in the Las Vegas began deliberating to determine whether Takeda Pharmaceuticals is liable for the bladder cancer of two women, both in their 80s, who were diagnosed with the disease after taking the diabetes drug Actos … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals |

Judge May Punish Lawyers for Misconduct in Actos Trial

Las Vegas district judge Kerry Earley is considering a request to punish lawyers for misconduct during a civil trial over the cancer risks associated with Takeda Pharmaceuticals’ diabetes drug Actos. On Thursday, Judge Earley heard arguments from an attorney representing … Continue reading

Posted in Actos, Health Concerns, Legal News, Pharmaceuticals |

Takeda May Not Pay Eli Lilly’s Portion of Actos Injury Lawsuit

Eli Lilly & Co. has indicated that its former marketing partner, Takeda Pharmaceutical Co., may not pay Lilly’s share of a recent United States jury verdict that ordered Takeda and Lilly to pay $9 billion in punitive damages in a … Continue reading

Posted in Actos, Legal News, Pharmaceuticals |

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.